Epichlorohydrin

CASRN 106-89-8

  • IRIS Summary (PDF) (24 pp, 167 K)
  • Status: Epichlorohydrin is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (24 pp, 167 K) last updated: 04/01/1992
Information reviewed but value not estimated.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (24 pp, 167 K) last updated: 04/01/1992

RfC (mg/m3) System Basis PoD Composite UF Confidence
1 x10-3 Respiratory Changes in the nasal turbinates NOAEL (HEC): 3.6 x10-1
mg/m3
300 Medium

Cancer Assessment


Weight of Evidence for Cancer (PDF) (24 pp, 167 K) last updated: 03/01/1988

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Human data are inadequate. Multiple studies in rats and mice administered epichlorohydrin by various routes were positive. As epichlorohydrin is a strong alkylating agent, tumors are produced at the site of application.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (24 pp, 167 K)

Oral Slope Factor: 9.9 x10 -3 per mg/kg-day
Drinking Water Unit Risk: 2.8 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Gastrointestinal
Tumor type(s): Papillomas and carcinomas of the forestomach (Konishi et al., 1980)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (24 pp, 167 K)

Inhalation Unit Risk: 1.2 x10 -6 per µg/m3
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Respiratory
Tumor type(s): Nasal cavity tumors (Laskin et al., 1980)


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.